|
Mar 8
|
Q4 2023 OptiNose Inc Earnings Call
|
|
Mar 7
|
OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...
|
|
Mar 7
|
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 7
|
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
|
|
Dec 6
|
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
|
|
Nov 17
|
Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),
|
|
Aug 12
|
OptiNose, Inc. (NASDAQ:OPTN) Q2 2023 Earnings Call Transcript
|
|
Aug 11
|
Q2 2023 OptiNose Inc Earnings Call
|
|
Aug 10
|
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
|
|
Aug 10
|
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
|
|
Aug 9
|
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
|